7 February 2023
DeepVerge PLC
("DeepVerge" or "the Company" or "the Group")
Board appointment
DeepVerge (AIM: DVRG), the environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins, is pleased to announce the immediate appointment of Andrew Waters FCA as Chief Financial Officer (CFO) and as a Director of the Company.
Andrew brings significant experience as a CFO of both public and private companies in the healthcare and life sciences field, including most recently at AIM quoted Venture Life Group plc. Andrew has a Physics degree from Imperial College and qualified as a Chartered Accountant with PriceWaterhouseCoopers.
As part of the process of strengthening the Board, a further independent Non-Executive Director will be appointed as soon as practicable.
Dr Nigel Burton, interim CEO DeepVerge plc, commented:
I'm pleased to welcome Andrew to the Board. In October 2022 we committed to strengthening the Board, including recruiting a new Group CFO, and are pleased to have been able to make this appointment in just over three months. As we seek to grow the Company through a combination of organic growth, joint ventures and collaborations, Andrew is a welcome addition to the Board with his relevant international financial and commercial experience.
Additional Disclosures Required under the AIM Rules for Companies
In accordance with Schedule 2(g) of the AIM Rules for Companies, Mark Andrew Waters (aged 56) is, or has been within the previous five years, a director or partner of the following companies or partnerships:
| Current directorships/partnerships | Past directorships/partnerships
|
| ACP1 Limited | Venture Life Group plc |
| Green Elements Capital Limited | Infirst Healthcare Limited |
| | Infirst Healthcare Inc. |
| | Lubatti Limited |
| | Periproducts Limited |
| | Respicopea Holdings Limited |
| | Respicopea Limited |
| | Immunicopea Limited |
| | Venture Life Limited |
| | Pharmasource BV |
| | MD Manufacturing BV |
| | Nelie BV |
Andrew Waters does not hold any ordinary shares in the Company.
Save as set out above, there is no further information to be disclosed in respect of Andrew Waters under Schedule 2(g) of the AIM Rules.
| DeepVerge plc | Nigel Burton, Interim CEO | +44 (0) 7785 234447 |
| SPARK Advisory Partners Limited (Nominated Adviser) | Neil Baldwin | +44 (0) 113 370 8974 |
| Turner Pope Investments (TPI) Limited (Broker) | Andy Thacker/James Pope | +44 (0) 20 3657 0050 |
Market Abuse Regulation (MAR) Disclosure
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
About DeepVerge plc (www.deepverge.com)
DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins; Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.